659 related articles for article (PubMed ID: 16011702)
1. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
3. Determining a maximum-tolerated schedule of a cytotoxic agent.
Braun TM; Yuan Z; Thall PF
Biometrics; 2005 Jun; 61(2):335-43. PubMed ID: 16011679
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
5. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
6. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
7. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
8. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
9. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
10. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
11. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
12. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
13. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
14. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
15. Phase II multi-step planning methods in oncology: comparison, recommendations and potential applications.
Medioni J; de Rycke Y; Tournoux Facon C; Mallet A; Asselain B
Contemp Clin Trials; 2007 May; 28(3):249-57. PubMed ID: 17113357
[TBL] [Abstract][Full Text] [Related]
16. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
Zohar S; Chevret S
Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
[TBL] [Abstract][Full Text] [Related]
17. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.
Goldman AI; Hannan PJ
Stat Med; 2001 Jun; 20(11):1575-89. PubMed ID: 11391689
[TBL] [Abstract][Full Text] [Related]
18. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
19. Continual reassessment method: a likelihood approach.
O'Quigley J; Shen LZ
Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
[TBL] [Abstract][Full Text] [Related]
20. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]